DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Aldoril (Methyldopa / Chlorothiazide) - Summary

 
 



WARNING

This fixed combination drug is not indicated for initial therapy of hypertension. Hypertension requires therapy titrated to the individual patient. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management. The treatment of hypertension is not static, but must be re-evaluated as conditions in each patient warrant.

 

ALDORIL SUMMARY

TABLETS
ALDORIL ®
(METHYLDOPA-HYDROCHLOROTHIAZIDE)

ALDORIL (Methyldopa-Hydrochlorothiazide) combines two antihypertensives: methyldopa and hydrochlorothiazide.

ALDORIL is indicated for the treatment of hypertension.


See all Aldoril indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Aldoril (Methyldopa / Chlorothiazide)

Vitamin D 'ineffective as treatment for hypertension'
Source: Cardiovascular / Cardiology News From Medical News Today [2015.03.19]
Researchers report that vitamin D supplementation does not work as an antihypertensive agent and cannot be recommended to control high blood pressure.

Cherokee Nation Keeps Hypertension in Check
Source: MedPage Today Cardiovascular [2015.03.19]
(MedPage Today) -- Million Hearts Champion Brett Gray says showing patients you care is key to compliance.

ACC: Folate Supplements Cut Strokes in Hypertension
Source: MedPage Today Cardiovascular [2015.03.19]
(MedPage Today) -- Hypertensive patients with low blood folate levels gain big benefit.

Lowering Ocular Hypertension Meds Needn't Boost Glaucoma Risk
Source: Medscape Ophthalmology Headlines [2015.03.18]
Patients with ocular hypertension (OH) can often lower their medication dosage and cut costs without a significantly increased glaucoma risk, Chinese researchers say.
Reuters Health Information

Expanding blood pressure screenings beyond primary care can improve hypertension detection
Source: Hypertension News From Medical News Today [2015.03.16]
Expanding blood pressure screenings to non-primary care settings can help identify more patients with high blood pressure, commonly called hypertension, and could contribute to better hypertension...

more news >>

Published Studies Related to Aldoril (Methyldopa / Chlorothiazide)

Combination of a thiazide, a vasodilator and reserpine compared with methyldopa plus hydrochlorothiazide in the treatment of hypertension in Zimbabwe. [1990.03.03]
Brinerdin (Sandoz), a combination of a diuretic (clopamide 5 mg), a vasodilator (dihydro-ergocristine 0.5 mg) and reserpine (0.1 mg) (CDR) was compared with methyldopa (MD) plus hydrochlorothiazide (HCT) for antihypertensive effect, adverse reactions, compliance and patient preference in an open cross-over trial...

Evaluation of the efficacy and safety of enalapril plus hydrochlorothiazide plus methyldopa vs standard triple therapy in the treatment of moderate to severe hypertension: results from a multicentre study. [1990.02]
We report the results of a randomized, double-blind, parallel group multicentre study in 120 patients with moderate to severe hypertension, comparing two different types of antihypertensive treatment: a) the standard 'triple therapy' with hydrochlorothiazide, propranolol and hydralazine, and b) the combination of an ACE inhibitor, enalapril with hydrochlorothiazide (HCTZ) and methyldopa...

Oral enalapril-hydrochlorothiazide-methyldopa as first line treatment for severe hypertension in Nigerians. [2004.01]
A combination of low-dose oral enalapril, methyldopa and hydrochlorothiazide was evaluated in the acute treatment of severe hypertension. Blood pressure moved from an average 210/120 mmHg at the onset to an average 135/79 mmHg within 24 hours, without any significant side effects and at about half the cost of commonly used parenteral hydralazine..

more studies >>


Page last updated: 2015-03-19

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015